Improving Awakening Prognostication After Non Anoxic Coma Using PET-MRI in Intensive Care Unit (ETIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02798588
Recruitment Status : Recruiting
First Posted : June 14, 2016
Last Update Posted : July 26, 2018
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

In last decades, several advances in the neuro-intensive management have lead to decrease mortality in Intensive Care Units. A significant morbidity remains as patients survive after a traumatic coma with uncertain quality of awakening and a high risk of functional disability. Predicting awareness recovery and functional disability of those who will awake constitutes a major challenge to inform patients' relatives, to give the best chances in terms of rehabilitation resources or to adapt intensive cares to a reasonable level. Tools currently available are not sufficient neither to predict bad awakening outcome nor to predict good functional outcome. In many countries, life's support cessation is a constant call for robust evaluation as soon as possible in ICU but it is mandatory to reach a positive predictive value of non-awaking close to 100%. Many clinical, electro-physiological, biological, radiological and functional parameters have been conducted with comatose patients assuming the purpose to predict outcome. Regarding unfavourable outcome, the gold standard is the abolition of the N20 component of somatosensory evoked potentials but the specificity is high enough only for patients with anoxic coma. Several neurophysiological markers such as MMN, P300 are correlated to a favourable outcome but the sensitivity and specificity remains low for patients who suffered a severe traumatic brain injury. New Diffusion Tensor imaging sequences provide complementary information to detect small structural lesions (diffuse axonal lesions). Recently, functional MRI analyzing Resting State has also been proposed as a prognostic marker during coma. PET using Fluoro-Desoxy-Glucose is able to assess the metabolism in key regions of the awakening network in either anaesthesia or sleep. Recent studies have reported interesting results at the chronic stage but to knowledge, these tools have only been used to address pathophysiology's issues and never to improve coma prognosis at the initial stage. The investigators hypothesize that the heterogeneity of the population requires a global and accurate assessment of the central nervous system, combining structural, metabolic and functional information in order to refine the prognosis.

The protocol integrates in one-sequence most radiological markers of brain injury within a unique PET-MRI in Lyon. The most relevant originality of the study consists in confronting FDG-PET and MRI sequences to a large clinical, electrophysiological and biological battery. The added clinical value would be to question the synergistic effect of each parameter and to find out which ones are the most useful for awakening prediction, as they have not been compared in a multi-parametric database.

PET-MRI, as a new device combining physiological and prognostic questioning, allows us:

  • to implement a more integrative physio-pathological analysis
  • to avoid the cofounding effect of awareness' fluctuations in recording simultaneously multiple functional imaging techniques.

The RS will be analyzed at 2 epochs in order to assess the stability of brain connectivity, related to neuronal activity (glucose metabolism) and brain perfusion.

Condition or disease Intervention/treatment Phase
Coma Radiation: PET-MRI Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Improving Awakening Prognostication After Non Anoxic Coma Using PET-MRI in Intensive Care Unit
Actual Study Start Date : February 16, 2017
Estimated Primary Completion Date : August 16, 2020
Estimated Study Completion Date : August 16, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Coma

Arm Intervention/treatment
Experimental: Comatose patients in ICU Radiation: PET-MRI
18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition

Primary Outcome Measures :
  1. Analysis of feasibility (pilot study) with Number of patients included during a 12-months period [ Time Frame: at 12 months ]
  2. Analysis of feasibility (pilot study) with ratio of patient included vs patient admissible according to the screening [ Time Frame: at 12 months ]
  3. Analysis of feasibility (pilot study) with respect of deadline for completion of PET MRI [ Time Frame: at 12 months ]
  4. Analysis of security (pilot study) with tolerance of the PET-MRI [ Time Frame: at 12 months ]

Secondary Outcome Measures :
  1. Unfavorable clinical evolution towards awareness (dichotomic criteria : absence of awareness with functional communication) [ Time Frame: at 12 month ]
    Building a prognostic tool including miscellaneous parameters (clinical, biological, electrophysiological, metabolic PET and multimodal MRI) for the prediction of an unfavourable outcome (death, vegetative state, minimally conscious state) at 1 year after a non-anoxic brain injury (focal or multifocal; either traumatic or vascular causes)

  2. Unfavorable clinical evolution in absence of awareness (ordinal criteria within unfavorable outcome) with Coma Recovery Scale-Revised [ Time Frame: at 12 month ]

    Defining an association of criteria, which are available in the 1st month after coma, that are able to predict at 1 year with a high positive predictive value the level of disorder of consciousness in the subgroup with unfavourable outcome in analyzing (according to Coma Recovery Scale-Revised) the evolution of :

    • vegetative state patients
    • minimally-conscious patients
    • dead patients

  3. Functional clinical evolution in presence of awareness (ordinal criteria within favorable outcome) according to Glasgow Outcome Scale (GOS) [ Time Frame: at 12 month ]
    Defining an association of criteria which are available in the 1st month after coma, that are able to predict at 1 year with a high positive predictive value the quality of functional outcome in the subgroup with favourable outcome in analyzing the level of autonomy according to Glasgow Outcome Scale (GOS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients presenting either vascular or traumatic lesions
  2. Patients with no response to simple command 48h after sedation's cessation
  3. Patients included between 7 days (to reduce the effect of early oedema) and 30 days after the coma (to control the homogeneity of our cohort)
  4. Patients included between 18 and 75 years old, to limit the risk of care withdrawal for poor previous medical condition
  5. Patients evaluated by a global electrophysiological assessment at beside in ICU in a short delay before or after PET-MRI

Exclusion Criteria:

  1. Patient with an associated anoxic encephalopathy
  2. Patients with contra-indication to MRI
  3. Patients with hypersensibility to the active molecules (FDG) or to one of this excipient
  4. Pregnant women
  5. Minor patients
  6. Patients under legal protection
  7. Patients not affiliated to French health care system
  8. Patients in poor medical condition (hemodynamic, respiratory instability)
  9. Patients moribund or with previous decision of care withdrawal
  10. Absence of relatives to give written consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02798588

Contact: Florent GOBERT, MD 04 72 68 12 96 ext +33

Réanimation polyvalente neurologique Hôpital Neurologique HCL Recruiting
Bron, France, 69500
Contact: Florent GOBERT, MD    04 72 68 12 96 ext +33   
Sub-Investigator: Frédéric DAILLER, MD         
Sub-Investigator: Jacques LUAUTE, MD         
Sub-Investigator: Nathalie ANDRE-OBADIA, MD         
Principal Investigator: Florent GOBERT, MD         
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Florent GOBERT, MD Réanimation polyvalente neurologique Hospices Civils de Lyon

Responsible Party: Hospices Civils de Lyon Identifier: NCT02798588     History of Changes
Other Study ID Numbers: 69HCL15_0669
2015-A01886-43 ( Other Identifier: ID-RCB )
First Posted: June 14, 2016    Key Record Dates
Last Update Posted: July 26, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Hospices Civils de Lyon:
comparative study
functional imaging

Additional relevant MeSH terms:
Consciousness Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms